Entera Bio Ltd.
Entera Bio Ltd. (ENTX): 12 pipeline candidates · ~12 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.8 months
D/E 0.23 · 2% dilution
Lead: Phase 3
12 candidates
N/A
8 buys · 0 sells (180d)
A transparent, data-derived signal for Entera Bio Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$59.1M
Cash
$12.0M
Quarterly Burn
$3.1M
Runway
11.8 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| eb612 | Phase 2 |
| eb613 | Phase 3 |
| ebp05 | Phase 1 |
| ebp11 | Phase 1 |
| ebp11-f1 | Phase 1 |
| ebp11-f2 | Phase 1 |
| ebp11-f4 | Phase 1 |
| ebp11-f5 | Phase 1 |
| ebp22 | Phase 1 |
| forteo | Phase 1 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Entera Bio Ltd.'s pipeline?
Entera Bio Ltd. (ENTX) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Entera Bio Ltd.'s lead drug candidate?
Entera Bio Ltd.'s most advanced tracked candidate is eb612 (Phase 2) for Hypoparathyroidism.
What is Entera Bio Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Entera Bio Ltd. has approximately 11.8 months of cash runway.
What is Entera Bio Ltd.'s market capitalization?
Entera Bio Ltd.'s market capitalization is approximately $59.1M.
Who is the CEO of Entera Bio Ltd.?
Ms. Miranda J. Toledano M.B.A. is the chief executive officer of Entera Bio Ltd. (ENTX).
Get the full picture on Entera Bio Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.